Novavax, Inc. (NASDAQ: NVAX)

Novavax, Inc. (NASDAQ: NVAX), a clinical stage biotechnology company, is focused on creating innovative vaccines that target a wide array of infectious diseases using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP based, potent, recombinant vaccines by leveraging new and efficient manufacturing approaches. Novavax’s long-term goal is to be able to deliver a customized vaccine in the midst of an epidemic. For further information, visit the Company’s web site at www.novavax.com.